Systemic hyperthermia masks the neuroprotective effects of MK-801, but not rosiglitazone in brain ischaemia.

Abstract

The use of neuroprotective agents has been under investigation for the treatment of ischaemic brain stroke. In this study, we examined the effects of rosiglitazone and MK-801, two potential neuroprotectants, on thromboembloic focal stroke in hyperthermic rats. The animals were assigned into groups of rosiglitazone, MK-801 and control, all under both normothermic and hyperthermic conditions. A focal ischaemia was induced by injection of preformed clot into the origin of the middle cerebral artery. The animals were assessed by measuring infarct size and brain oedema and also evaluating neurological deficit and seizure activity. Rosiglitazone improved infarct volume and neurological deficit in both normo- (36%) and hyperthermic (63%) animals; but MK-801 only improved normothermic animals. Our results do not support the use of MK-801 in hyperthermic conditions of brain stroke but suggest that rosiglitazone may preserve its efficiency even in hyperthermia.

• Authors: Mohsen Nategh, Kaveh Shaveisi, Alireza P Shabanzadeh, Seyed Sh Sadr, Mohsen Parviz, Mojdeh Ghabaei
• Journal: Basic & clinical pharmacology & toxicology (Basic Clin Pharmacol Toxicol) Vol. 107 Issue 3 Pg. 724-9 (Sep 2010) ISSN: 1742-7843 [Electronic] England
• PMID: 20406202 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Neuroprotective Agents
• Thiazolidinediones
• Rosiglitazone
• Dizocilpine Maleate

Topics

• Animals
• Brain Ischemia (chemically induced, drug therapy, pathology)
• Disease Models, Animal
• Dizocilpine Maleate (therapeutic use)
• Fever (chemically induced, drug therapy)
• Male
• Neuroprotective Agents (therapeutic use)
• Rats
• Rats, Wistar
• Rosiglitazone
• Thiazolidinediones (therapeutic use)